POLB vs. REDX, ETX, SBTX, COS, C4XD, DDDD, TRX, FUM, OKYO, and AOR
Should you be buying Poolbeg Pharma stock or one of its competitors? The main competitors of Poolbeg Pharma include Redx Pharma (REDX), e-therapeutics (ETX), SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), Tissue Regenix Group (TRX), Futura Medical (FUM), OKYO Pharma (OKYO), and AorTech International (AOR). These companies are all part of the "biotechnology" industry.
Poolbeg Pharma vs.
Redx Pharma (LON:REDX) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.
Redx Pharma has a beta of -0.53, meaning that its stock price is 153% less volatile than the S&P 500. Comparatively, Poolbeg Pharma has a beta of 2.11, meaning that its stock price is 111% more volatile than the S&P 500.
In the previous week, Poolbeg Pharma had 1 more articles in the media than Redx Pharma. MarketBeat recorded 1 mentions for Poolbeg Pharma and 0 mentions for Redx Pharma. Poolbeg Pharma's average media sentiment score of 0.40 beat Redx Pharma's score of 0.00 indicating that Poolbeg Pharma is being referred to more favorably in the news media.
Redx Pharma has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.
Poolbeg Pharma's return on equity of -32.56% beat Redx Pharma's return on equity.
72.7% of Redx Pharma shares are owned by institutional investors. Comparatively, 1.2% of Poolbeg Pharma shares are owned by institutional investors. 18.4% of Redx Pharma shares are owned by company insiders. Comparatively, 24.7% of Poolbeg Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Redx Pharma received 153 more outperform votes than Poolbeg Pharma when rated by MarketBeat users. Likewise, 73.56% of users gave Redx Pharma an outperform vote while only 0.00% of users gave Poolbeg Pharma an outperform vote.
Summary
Poolbeg Pharma beats Redx Pharma on 7 of the 13 factors compared between the two stocks.
Get Poolbeg Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for POLB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Poolbeg Pharma Competitors List
Related Companies and Tools
This page (LON:POLB) was last updated on 5/22/2025 by MarketBeat.com Staff
